Search Results
Viewing: 7841-7850 of 11765 | All
Article
Our Healing Environment
When your child needs a hospital, everything matters. Years of careful planning paved the way. There are thousands of moving parts involved in opening a new main hospital. More than 8,000 tasks to be precise.
Article
New Nationwide Children’s Tower
The new Nationwide Children’s Hospital patient tower is the largest single construction project in the hospital’s history. When it opens in 2028 as a companion to our existing patient tower, it will be home to the most advanced, life-changing specialty services in all of pediatric medicine.
News
Nationwide Children’s Hospital Announces Strategic Plan: $3.3 Billion Commitment to Address Health of the Whole Child in Unique Care Model
COLUMBUS – Nationwide Children’s Hospital announced today the most ambitious strategic plan in its 129-year history. A five-year, $3.3 billion commitment aimed at transforming health outcomes for children locally and around the world, will invest in hallmark programs, talent, and
Specialty
The Center for Clinical Excellence
Be a Zero Hero! Quality, safety and best outcomes are our top priorities. We have many goals and tools that help us quantify the healthcare process Learn how we do it.
Partnerships and Collaborations
Collaboration is a critical part of Nationwide Children's Hospital strategy to improve the lives of children everywhere, and these initiatives cannot happen without strong partnerships.
News
FDA Approves First Gene Therapy Treatment for SMA Developed at the Abigail Wexner Research Institute at Nationwide Children’s Hospital
Today, the Abigail Wexner Research Institute at Nationwide Children’s Hospital praised the Food and Drug Administration (FDA) for its approval of Zolgensma® for spinal muscular atrophy (SMA) following decades of research in its Center for Gene Therapy to help patients with neuromuscular diseases.
News
FDA Approves First Gene Therapy Treatment for Duchenne Muscular Dystrophy Developed at the Abigail Wexner Research Institute at Nationwide Children’s Hospital
Today, the Abigail Wexner Research Institute at Nationwide Children’s Hospital praised the Food and Drug Administration (FDA) for its accelerated approval of SRP-9001/ELEVIDYS for Duchenne muscular dystrophy (DMD) following decades of research in its Center for Gene Therapy to help patients with neuromuscular diseases.
Article
Flanigan Lab
Under the direction of Kevin Flanigan, MD, the Flanigan Lab focuses on the genetic and molecular characterization of inherited neuromuscular diseases, and toward the development of therapies directed toward these diseases.
Article
Resources
Learn more about the resources offered by the Biopathology Center at Nationwide Children's Hospital.
Article
About
Learn more about the Biopathology Center, part of the Abigail Wexner Research Institute at Nationwide Children’s Hospital.